Form 4: Edgewise Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Joanne M. Donovan, CMO of Edgewise Therapeutics, Inc., sold 9,441 shares of common stock on August 12, 2026.

Summary

  • Option exercise/conversion: acquired 5,781 Common Stock on August 12, 2026; holds 11,035 after (Direct).
  • Option exercise/conversion: acquired 7,031 Common Stock on August 12, 2026; holds 18,066 after (Direct).
  • Open-market sale: disposed of 2,839 Common Stock at $43.78 ($124,303) on August 12, 2026; holds 15,227 after (Direct).
  • Open-market sale: disposed of 2,779 Common Stock at $43.71 ($121,463) on August 12, 2026; holds 12,448 after (Direct).
  • Open-market sale: disposed of 104 Common Stock at $44.43 ($4,620) on August 12, 2026; holds 12,344 after (Direct).
  • Open-market sale: disposed of 800 Common Stock at $44.52 ($35,614) on August 12, 2026; holds 11,544 after (Direct).
  • Open-market sale: disposed of 2,919 Common Stock at $43.41 ($126,704) on August 13, 2026; holds 8,625 after (Direct).
  • Option exercise/conversion: disposed of 5,781 Restricted Stock Units on August 12, 2026; holds 11,563 after (Direct).
  • Option exercise/conversion: disposed of 7,031 Restricted Stock Units on August 12, 2026; holds 21,094 after (Direct).
  • Grant/award: acquired 32,500 Restricted Stock Units on August 12, 2026; holds 32,500 after (Direct).
  • Grant/award: acquired 65,000 Stock Option (Right to Buy) on August 12, 2026; holds 65,000 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $412,703 of stock on the open market.

Insider Transactions

Joanne M. Donovan — Officer (CMO)

DateTransactionSecuritySharesPriceValueHeld After
2026-08-12Option exercise/conversionCommon Stock5,781——11,035
2026-08-12Option exercise/conversionCommon Stock7,031——18,066
2026-08-12Open-market saleCommon Stock2,839$44$124.3K15,227
2026-08-12Open-market saleCommon Stock2,779$44$121.5K12,448
2026-08-12Open-market saleCommon Stock104$44$4.6K12,344
2026-08-12Open-market saleCommon Stock800$45$35.6K11,544
2026-08-13Open-market saleCommon Stock2,919$43$126.7K8,625
2026-08-12Option exercise/conversionRestricted Stock Units5,781——11,563
2026-08-12Option exercise/conversionRestricted Stock Units7,031——21,094
2026-08-12Grant/awardRestricted Stock Units32,500——32,500
2026-08-12Grant/awardStock Option (Right to Buy)65,000——65,000

Key Dates

DateDescription
2026-08-12Option exercise/conversion (5,781 shares)
2026-08-12Option exercise/conversion (7,031 shares)
2026-08-12Open-market sale (2,839 shares)
2026-08-12Open-market sale (2,779 shares)
2026-08-12Open-market sale (104 shares)
2026-08-12Open-market sale (800 shares)
2026-08-13Open-market sale (2,919 shares)
2026-08-12Option exercise/conversion (5,781 shares)
2026-08-12Option exercise/conversion (7,031 shares)
2026-08-12Grant/award (32,500 shares)
2026-08-12Grant/award (65,000 shares)

Keywords

insider transaction, Form 4, EWTX, Edgewise Therapeutics, Inc., bearish, Joanne M. Donovan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.